Discover how Mankind Pharma grew into a ₹90,000 crore company through affordable medicines, strong distribution, and smart business strategies.
Few Indian companies have reshaped an industry as quietly and effectively as Mankind Pharma. Founded in 1995 with an initial investment of just ₹50 lakh, the company has grown into one of India’s largest pharmaceutical businesses, with a market capitalization that has touched ₹96,700 crore and a strong presence across both prescription medicines and consumer healthcare.
Unlike many corporate success stories backed by venture capital or business dynasties, Mankind Pharma was built by two brothers from Meerut, Ramesh Juneja and Rajeev Juneja, whose greatest advantage was not financial capital but an intimate understanding of India’s healthcare realities.
Their journey demonstrates how identifying an overlooked market and solving a fundamental problem with disciplined execution can create one of the country’s most valuable enterprises.
A Salesman’s Education Across Rural India
Born in 1955 in Meerut, Uttar Pradesh, Ramesh Juneja grew up in a modest middle-class family with no connection to the pharmaceutical industry. After completing his science degree, he joined KeePharma Ltd. in 1974 as a medical representative, a role that required him to travel nearly 85 kilometres every day across small towns and villages in western Uttar Pradesh.
His routine consisted of long bus journeys, repeated visits to clinics, conversations with doctors, and constant efforts to promote medicines in markets where affordability mattered far more than brand recognition. Although the work was physically demanding and often unrewarding, those years gave him something far more valuable than a formal management education.
They allowed him to understand how medicines reached patients, how doctors made prescribing decisions, and why millions of Indians struggled to complete even basic medical treatments.
The Experience That Defined His Mission
One encounter during those early years remained with Ramesh long after it had ended. At a small-town pharmacy, he watched a patient arrive with a doctor’s prescription but without enough money to purchase the required medicines. Hoping the chemist would trust him, the man placed his silver jewellery on the counter as security. The chemist declined, and the patient walked away empty-handed.
Years later, Ramesh Juneja recalled that moment in Mankind Pharma’s annual report, writing, “Most patients who came for doctor consultations had limited money. After paying the consultation fee, they were unable to afford medicines and had to opt for partial medications. That image never left me.” The incident became more than a memory.
It evolved into the central idea behind the company he would eventually build, proving that India’s biggest healthcare challenge was not merely access to doctors but access to affordable medicines.
Learning Through Failure Before Success
Ramesh’s growing understanding of the pharmaceutical business led him to Lupin Limited in 1975, where he spent nearly eight years in managerial roles, gaining deeper exposure to manufacturing, distribution, marketing, and sales operations. Confident that he understood the industry well enough to build something of his own, he left Lupin in 1983 to establish Bestochem, a pharmaceutical formulations business based in Meerut.
The venture never achieved the scale he had envisioned. Limited resources, execution challenges, and a highly competitive market prevented Bestochem from growing into a sustainable business. After more than a decade of struggle, Ramesh exited the company in 1994. In hindsight, however, Bestochem became an invaluable learning experience.
It taught him that affordable pricing alone could not build a successful pharmaceutical company. Long-term success required manufacturing partnerships, disciplined distribution, trusted brands, and operational excellence working together.
Building Mankind Pharma With ₹50 Lakh
In 1995, Ramesh decided to begin again, this time alongside his younger brother Rajeev Juneja, who had developed practical knowledge of the pharmaceutical business while working at a medical store. Together they invested ₹50 lakh of their own savings to establish Mankind Pharma, without venture capital, institutional investors, or private equity funding.
Their ambition was straightforward yet ambitious: produce high-quality medicines that ordinary Indians could genuinely afford while building a company capable of reaching the markets that larger pharmaceutical firms had largely ignored.
The brothers recruited 25 medical representatives, many with backgrounds similar to Ramesh’s own, and began laying the foundation for what would eventually become one of India’s largest pharmaceutical sales networks.
A Business Strategy That Went Against the Industry
At a time when India’s largest pharmaceutical companies focused their resources on metropolitan hospitals and specialist doctors, Mankind deliberately expanded into Tier 2, Tier 3, and rural markets, where competition remained relatively limited but demand for affordable healthcare was enormous.
Instead of chasing premium urban customers, the company concentrated on building relationships with general physicians serving smaller towns across Uttar Pradesh, Bihar, Rajasthan, Haryana, Punjab, and Madhya Pradesh.
Pricing became another defining advantage. Mankind introduced branded medicines that were often 30 to 50 percent cheaper than comparable products offered by larger competitors. While many believed such pricing would permanently reduce profitability, the Juneja brothers believed affordability itself would become the company’s greatest competitive advantage. Higher prescription volumes and stronger customer loyalty eventually validated that strategy.
Building Distribution Before Building Prestige
Rather than spending heavily on corporate branding during its early years, Mankind invested aggressively in expanding its distribution network. That decision created one of the company’s strongest competitive moats.
Today, Mankind Pharma reaches more than 600,000 medical practitioners, supplies over 700,000 pharmacies, and operates through approximately 16,000 field representatives across India.
This extensive network has enabled the company to establish a presence in nearly every district of the country while maintaining close relationships with doctors, chemists, and healthcare providers that many competitors have struggled to replicate.
Creating Consumer Brands Beyond Prescription Medicines
As the company matured, the Juneja brothers recognized that sustainable growth required more than prescription medicines. Mankind gradually expanded into consumer healthcare, building brands that became familiar to millions of Indian households.
Products such as Manforce, Prega News, Unwanted-72, Gas-O-Fast, HealthOK, and AcneStar successfully combined medical credibility with consumer recognition, allowing the company to diversify its revenue while strengthening its overall market position.
This balanced portfolio of prescription pharmaceuticals and over-the-counter products became one of Mankind’s defining strengths.
Expanding Manufacturing and Global Presence
To support its rapid growth, Mankind invested heavily in manufacturing infrastructure over the following decades. The company now operates more than 30 manufacturing facilities across India, producing tablets, capsules, injectables, syrups, ointments, APIs, and consumer healthcare products.
Beyond the domestic market, Mankind has expanded its international footprint by exporting medicines to over 34 countries across Asia, Africa, Latin America, and the CIS region, gradually transforming itself from a domestic pharmaceutical company into an international healthcare business.
The IPO That Marked a New Chapter
After nearly three decades of privately funded growth, Mankind Pharma entered the public markets in May 2023 with a ₹4,326 crore Initial Public Offering, one of India’s largest pharmaceutical IPOs. The issue was subscribed more than 15 times, reflecting strong confidence from institutional as well as retail investors.
The listing not only rewarded the founders’ long-term vision but also positioned Mankind among India’s most valuable listed pharmaceutical companies.
Financial Strength and Industry Leadership
The company’s financial performance has reflected the consistency of its business model. According to its FY2025 Annual Report, Mankind Pharma generated revenue exceeding ₹12,000 crore, maintained EBITDA above ₹3,000 crore, and reported net profit of more than ₹2,000 crore.
From an initial investment of just ₹50 lakh, the business has grown into a pharmaceutical leader valued at nearly ₹90,000 crore, making it one of India’s most remarkable examples of long-term value creation.
Strengthening the Portfolio Through Strategic Acquisitions
Mankind Pharma has complemented organic growth with carefully selected acquisitions. In 2024, the company completed the acquisition of Bharat Serums and Vaccines (BSV) for approximately ₹13,768 crore, one of the largest transactions in the history of India’s pharmaceutical sector.
The acquisition significantly strengthened Mankind’s presence in women’s health, fertility treatment, critical care, and biologics while expanding its portfolio into higher-value therapeutic segments.
The Legacy of the Juneja Brothers
Today, Mankind Pharma stands as one of India’s leading pharmaceutical companies not because it pursued the most glamorous markets or the highest-priced medicines, but because it built its business around a problem that affected millions of ordinary Indians. Ramesh Juneja transformed decades of field experience into a clear business philosophy, while Rajeev Juneja helped build brands, distribution, and commercial discipline that sustained the company’s growth over three decades.
From a ₹50 lakh investment in 1995 to a company worth nearly ₹90,000 crore, Mankind Pharma’s journey illustrates that enduring businesses are often built not by chasing the most visible opportunities, but by solving the problems that others overlook. Its success is rooted in affordability, execution, and an unwavering commitment to making quality healthcare accessible to a far larger section of India’s population.
Source: Business Connect
Photo: AAJ TAK
